The most frequently asked questions
The Galleri test is a qualitative, next-generation sequencing-based, in vitro diagnostic test intended for the detection of DNA methylation patterns using cell-free DNA (cfDNA) isolated from human peripheral whole blood. DNA methylation is a natural process used by cells to regulate gene expression. Certain DNA methylation patterns can serve as a signal of cancer and provide information about the origin of the cancer signal.
The Galleri test detects methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer. When a cancer signal is detected, the test predicts the origin of the cancer signal with high accuracy. The Galleri test does not detect specific genetic mutations and does not determine an individual’s genetic risk for cancer. Learn more about the Galleri test.
The Galleri test is only commercially available in the US at this time. The Galleri test will be available to eligible patients as part of a clinical study in partnership with the United Kingdom’s National Health Service (NHS) in mid-2021. More details provided here.
The Galleri test should be used in addition to guideline-recommended cancer screening, such as mammography, colonoscopy, prostate specific antigen (PSA) or cervical cancer screening. Galleri can benefit patients with an elevated risk of cancer due to age, such as those aged 50 or older.
The list price for the Galleri test is $949. Contact your account representative or GRAIL Customer Service at (833) 694‑2553 or customerservice@grail.com if you have questions about pricing.